Active Ingredient(s): Panitumumab
FDA Approved: * September 27, 2006
Pharm Company: * AMGEN
Category: Cancer

Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). Panitumumab is manufactured by Amgen and marketed as Vectibix. It was originally developed by Abgenix Inc. In 2014, Amgen and Illumina entered into an agreement to develop a companion diagnostic to accompany panitumumab.[1] Contents 1 Medical uses 2 Contraindications 3 Adverse effects 4 Phar... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Vectibix 100 mg/5ml Intravenous Solution
NDC: 55513-954
Amgen Inc
Vectibix 200 mg/10ml Intravenous Solution
NDC: 55513-955
Amgen Inc
Vectibix 400 mg/20ml Intravenous Solution
NDC: 55513-956
Amgen Inc